A phase II trial of LBH589 in refractory myelodysplastic syndromes (MDS) patients
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2015
At a glance
- Drugs Panobinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 12 Nov 2015 Status changed from completed to discontinued as reported by
- 03 May 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 May 2011 Planned end date changed from 1 Jan 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.